Search Within

Eytan Moshe Stein

Formats
  1. Meeting Abstract (217)
  2. Journal Article (104)
  3. Review (17)
  4. Research Letter (14)
  5. Editorial (5)
  6. Book Section (3)
  7. Guidelines (2)
  8. Correspondence (1)
  9. Miscellaneous (1)
Groups
  1. Adult Leukemia (364)
  2. Center for Hematologic Malignancies (364)
  3. Department of Medicine (364)
  4. Hematologic Malignancies, Division of (364)
  5. GSK Faculty (92)
  6. Executive Committee, Center for Hematologic Malignancies (87)

More Groups

People
  1. Martin Tallman (116)
  2. Ross Levine (75)
  3. Aaron Goldberg (41)
  4. Jan Bewersdorf (33)
  5. Andriy Derkach (31)
  6. Christopher Famulare (30)

More People

Years
  1. 2025 (14)
  2. 2024 (44)
  3. 2023 (49)
  4. 2022 (34)
  5. 2021 (31)
  6. 2020 (30)

More Years

Publications
  1. Blood (170)
  2. Journal of Clinical Oncology (23)
  3. Clinical Lymphoma, Myeloma and Leukemia (17)
  4. Haematologica (16)
  5. Blood Advances (14)
  6. Leukemia and Lymphoma (12)

More Publications

Publishers
  1. American Society of Hematology (185)
  2. Elsevier Inc. (30)
  3. American Society of Clinical Oncology (27)
  4. Ferrata Storti Foundation (16)
  5. Nature Publishing Group (15)
  6. Taylor & Francis Group (12)

More Publishers

Results (364)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Overall survival (OS) by IDH2 mutant allele (R140 or R172) in patients with late-stage, mutant-IDH2 relapsed/refractory acute myeloid leukemia (AML) treated with enasidenib or conventional care regimens (CCR) in the randomized, open-label, phase 3 IDHENTIFY trial
    Meeting Abstract

    DiNardo, C. D.; de Botton, S.; Risueño, A.; Schuh, A. C.; Lowenberg, B.; Kim, H. J.; Vyas, P.; Wei, A. H.; Stein, E. M.; Döhner, H.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save
  • First results of a phase II study (STIMULUS-AML1) investigating sabatolimab plus azacitidine plus venetoclax in patients with newly diagnosed acute myeloid leukemia (ND AML)
    Meeting Abstract

    Zeidan, A. M.; Westermann, J.; Kovacsovics, T.; Assouline, S.; Schuh, A. C.; Kim, H. J.; Macias, G. R.; Sanford, D.; Luskin, M. R.; Stein, E. M.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save
  • Siremadlin in combination with venetoclax (VEN) plus azacitidine (AZA) in adult patients with acute myeloid leukemia (AML) who are ineligible for intensive chemotherapy: A phase Ib/II trial
    Meeting Abstract

    Daver, N.; Wei, A. H.; Stein, E.; DeAngelo, D. J.; Pathak, D.; Xu, Y.; Grzesiak, S.; Venditti, A.
    Blood (2022)

    Fulltext@MSK | Save
  • A phase 1b study of IDH inhibition with enasidenib and MEK inhibition with cobimetinib in patients with relapsed or refractory acute myeloid leukemia who have co-occurring IDH2 and RAS signaling gene mutations
    Meeting Abstract

    Ball, B. J.; Stein, E.; Robbins, M.; Zhang, J.; Levine, R. L.; Synold, T.; Stein, A. S.; Marcucci, G.; Liu, Y.; Danilov, A. V.
    Blood (2022)

    Fulltext@MSK | Save
  • A Phase 1b dose escalation and expansion study of SNDX-5613, azacitidine (AZA) and venetoclax (VEN) in newly diagnosed, patients ≥ 60 years with untreated NPM1-mutated/ FLT3-wild type AML or KMT2A-rearranged acute myeloid leukemia (AML)
    Meeting Abstract

    Zeidner, J. F.; Foster, M. C.; Johnson, M.; Huang, Y.; Swords, R. T.; Stein, E.; Foran, J. M.; Baer, M. R.; Stock, W.; Madanat, Y. F.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • A phase II clinical trial of E7820 for patients with relapsed/refractory myeloid malignancies with mutations in splicing factor genes
    Meeting Abstract

    Bewersdorf, J. P.; Stahl, M. F.; Taylor, J.; Chandhok, N. S.; Watts, J.; Derkach, A.; Wysocki, M.; Kostantakis, V.; Lu, S. X.; Bourcier, J.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Phase I study of ruxolitinib in combination with abemaciclib for patients with primary or post-polycythemia vera/ essential thrombocythemia myelofibrosis
    Meeting Abstract

    Bewersdorf, J. P.; Verstovsek, S.; Derkach, A.; Masarova, L.; Pemmaraju, N.; Stein, E.; Mauro, M.; Rampal, R. K.; Bose, P.
    Blood (2022)

    Fulltext@MSK | Save
  • Entospletinib (ENTO) in combination with cytarabine (Ara-C) and daunorubicin (DNR) in newly diagnosed (ND) adult patients with NPM1-mutated and FLT3-ITD wild-type acute myeloid leukemia (AML) Is associated with good response and survival: A phase 2 sub-study of the beat AML master trial
    Meeting Abstract

    Borate, U.; Li, R.; Huang, Y.; Swords, R. T.; Traer, E.; Stein, E.; Foran, J. M.; Baer, M. R.; Duong, V. H.; Stock, W.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • A phase 2a/2b multicenter study of AG-946 in patients with anemia due to lower-risk myelodysplastic syndromes
    Meeting Abstract

    Al-Samkari, H.; Fenaux, P.; Sekeres, M. A.; Stein, E.; Sallman, D. A.; Brunner, A. M.; Gurov, X. D.; Yin, O.; Frisbie, M.; Xiao, J.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Initial results from SELECT-AML-1, a Phase 2 Study of tamibarotene in combination with venetoclax and azacitidine in RARA-positive newly diagnosed AML patients ineligible for standard induction chemotherapy
    Meeting Abstract

    Kambhampati, S.; McMahon, C. M.; Eghtedar, A.; Pollyea, D. A.; de Botton, S.; Pigneux, A.; Cherry, M.; Ball, B. J.; Borthakur, G.; Cluzeau, T.; more...
    Blood (2022)

    Fulltext@MSK | Save